Cure My Disease

Don't miss your cure!

 Log in / Sign up

New immune drug shows promise in early trial for Hard-to-Treat cancers

NCT ID NCT05081609

Ongoing Disease control Sponsor: Ascendis Pharma Oncology Division A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not responded to standard care. The main goals are to check safety and find the best dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

TransCon IL-2 β/γ (an experimental immune-boosting drug)

What this could lead to

If successful, this could provide a new treatment option for several advanced solid tumors that have stopped responding to standard therapies.

What could go wrong

This is an early-phase trial (first in humans), so safety and effectiveness are not yet proven. The drug may cause significant side effects or fail to shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma HER2 positive breast carcinoma melanoma metastatic malignant neoplasm neoplasm Neoplasm Metastasis non-small cell lung carcinoma ovarian cancer ovarian carcinoma small cell lung carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

2L+ CERVICAL CANCER ADVANCED SOLID TUMOR LOCALLY ADVANCED SOLID TUMOR METASTATIC SOLID TUMOR NEOADJUVANT MELANOMA NEOADJUVANT NON-SMALL CELL LUNG CANCER PLATINUM-RESISTANT OVARIAN CANCER POST ANTI-PD-(L)1 NON-SMALL CELL LUNG CANCER POST ANTI-PD-(L)1 SMALL CELL LUNG CANCER POST ANTI-PD-1 MELANOMA SECOND OR THIRD LINE (2L/3L) CERVICAL CANCER THIRD LINE OR LATER (3L+) HER2+ BREAST CANCER THIRD-LINE OR LATER (3L+) PLATINUM-RESISTANT OVARIAN CANCER (PROC)

Contacts and locations

Locations

  • Ascendis Pharma Investigational Site

    Los Angeles, California, 90048, United States

  • Ascendis Pharma Investigational Site

    Los Angeles, California, 90067, United States

  • Ascendis Pharma Investigational Site

    Springfield, Illinois, 62702, United States

  • Ascendis Pharma Investigational Site

    Louisville, Kentucky, 40202, United States

  • Ascendis Pharma Investigational Site

    Boston, Massachusetts, 02114, United States

  • Ascendis Pharma Investigational Site

    Morristown, New Jersey, 07960, United States

  • Ascendis Pharma Investigational Site

    New York, New York, 10032, United States

  • Ascendis Pharma Investigational Site

    Huntersville, North Carolina, 28078, United States

  • Ascendis Pharma Investigational Site

    Canton, Ohio, 44718, United States

  • Ascendis Pharma Investigational Site

    Cincinnati, Ohio, 45219, United States

  • Ascendis Pharma Investigational Site

    Oklahoma City, Oklahoma, 73104, United States

  • Ascendis Pharma Investigational Site

    Pittsburgh, Pennsylvania, 15232, United States

  • Ascendis Pharma Investigational Site

    Nashville, Tennessee, 37203, United States

  • Ascendis Pharma Investigational Site

    Richmond, Virginia, 23298, United States

  • Ascendis Pharma Investigational Site

    Adelaide, 5000, Australia

  • Ascendis Pharma Investigational Site

    Adelaide, 5042, Australia

  • Ascendis Pharma Investigational Site

    Brisbane, 04120, Australia

  • Ascendis Pharma Investigational Site

    Frankston, 3199, Australia

  • Ascendis Pharma Investigational Site

    Southport, 4215, Australia

  • Ascendis Pharma Investigational Site

    Toorak Gardens, 05065, Australia

  • Ascendis Pharma Investigational Site

    Waratah, 2298, Australia

  • Ascendis Pharma Investigational Site

    Wilrijk, 2610, Belgium

  • Ascendis Pharma Investigational Site

    Montreal, H4A 3J1, Canada

  • Ascendis Pharma Investigational Site

    Toronto, M4N 3M5, Canada

  • Ascendis Pharma Investigational Site

    Toronto, M5G 2C4, Canada

  • Ascendis Pharma Investigational Site

    Cuneo, 12100, Italy

  • Ascendis Pharma Investigational Site

    Florence, 50134, Italy

  • Ascendis Pharma Investigational Site

    Grosseto, 58100, Italy

  • Ascendis Pharma Investigational Site

    Lido di Camaiore, 55041, Italy

  • Ascendis Pharma Investigational Site

    Livorno, 57124, Italy

  • Ascendis Pharma Investigational Site

    Meldola, 47014, Italy

  • Ascendis Pharma Investigational Site

    Milan, 20133, Italy

  • Ascendis Pharma Investigational Site

    Milan, 20141, Italy

  • Ascendis Pharma Investigational Site

    Modena, 41124, Italy

  • Ascendis Pharma Investigational Site

    Roma, 00167, Italy

  • Ascendis Pharma Investigational Site

    Torino, 10126, Italy

  • Ascendis Pharma Investigational Site

    Turin, 10060, Italy

  • Ascendis Pharma Investigational Site

    Verona, 37134, Italy

  • Ascendis Pharma Investigational Site

    Krakow, 31-501, Poland

  • Ascendis Pharma Investigational Site

    Poznan, 60693, Poland

  • Ascendis Pharma Investigational Site

    Warsaw, 02-781, Poland

  • Ascendis Pharma Investigational Site

    Singapore, 119228, Singapore

  • Ascendis Pharma Investigational Site

    Singapore, 217562, Singapore

  • Ascendis Pharma Investigational Site

    Seoul, Songpa-gu, 05505, South Korea

  • Ascendis Pharma Investigational Site

    Seongnam-si, 13620, South Korea

  • Ascendis Pharma Investigational Site

    Seoul, 03080, South Korea

  • Ascendis Pharma Investigational Site

    Seoul, 03722, South Korea

  • Ascendis Pharma Investigational Site

    Seoul, 06231, South Korea

  • Ascendis Pharma Investigational Site

    Seoul, 06351, South Korea

  • Ascendis Pharma Investigational Site

    Barcelona, 08023, Spain

  • Ascendis Pharma Investigational Site

    Barcelona, 08028, Spain

  • Ascendis Pharma Investigational Site

    Barcelona, 08035, Spain

  • Ascendis Pharma Investigational Site

    L'Hospitalet de Llobregat, 08908, Spain

  • Ascendis Pharma Investigational Site

    Madrid, 28006, Spain

  • Ascendis Pharma Investigational Site

    Madrid, 28027, Spain

  • Ascendis Pharma Investigational Site

    Madrid, 28040, Spain

  • Ascendis Pharma Investigational Site

    Madrid, 28041, Spain

  • Ascendis Pharma Investigational Site

    Madrid, 28050, Spain

  • Ascendis Pharma Investigational Site

    Málaga, 29010, Spain

  • Ascendis Pharma Investigational Site

    Murcia, 30120, Spain

  • Ascendis Pharma Investigational Site

    Oviedo, 33011, Spain

  • Ascendis Pharma Investigational Site

    Pamplona, 31008, Spain

  • Ascendis Pharma Investigational Site

    Seville, 41009, Spain

  • Ascendis Pharma Investigational Site

    Seville, 41014, Spain

  • Ascendis Pharma Investigational Site

    Valencia, 46009, Spain

  • Ascendis Pharma Investigational Site

    Valencia, 46014, Spain

  • Ascendis Pharma Investigational Site

    Taipei, 10002, Taiwan

  • Ascendis Pharma Investigational Site

    Taipei, 11259, Taiwan